Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension

American Journal of Hypertension

Volumn 10, Issue 1, 1997, Pages 117-123

  Pool, James L ^a   Cushman, William C ^b   Saini, Ravi K ^c   Nwachuku, Chuke E ^c   Battikha, Jean P ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

factorial design; fosinopril; hydrochlorothiazide; hypertension; quadratic response surface model

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROCHLOROTHIAZIDE; PLACEBO; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FACTORIAL ANALYSIS; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MODEL; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOSINOPRIL; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL;

EID: 0031025911     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00323-8     Document Type: Article

References (12)

1. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: The Joint National Committee fifth report. Arch Intern Med. 153:((2)):1993;149-152.
2. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 153:((2)):1993;154-183.
3. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 9:1987;36-42.
4. Opie LH. Angiotensin-Converting Enzyme Inhibitors: Scientific Basis for Clinical Use. 1992;Wiley-Liss, New York.
5. Wing LM, Chalmers JP, West MJ. Cross-over factorial studies with antihypertensive drugs. Nephron. 47:((suppl 1)):1987;94-98.
6. Chalmers J, Wing L, Taylor S. Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs. J Hypertens. 8:((suppl)):1990;S27-S35.
7. Goldberg MR, Offen WW, Rockhold FW. Factorial design: an approach to the assessment of therapeutic drug interactions in clinical trials. J Clin Res Drug Dev. 2:1988;215-225.
8. Goldberg MR, Rockhold FW, Offen WW, et al. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther. 46:((2)):1989;208-218.
9. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens. 11:((2)):1993;217-221.
10. Burris JF, Weir MR, Oparil S. An assessment of diltiazem and HCTZ in hypertension - application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 263:((11)):1990;1507-1512.
11. Mead R, Pike DJ. A review of response surface methodology from a biometric viewpoint. Biometrics. 31:1975;803-851.
12. Dupont AG. The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years. Cardiovasc Drugs Ther. 7:((suppl 1)):1993;55-62.